Overview

* 908 Devices ( MASS ) Q3 revenue decreases 4% yr/yr but beats analyst expectations

* Adjusted EBITDA loss improves 53% quarter over quarter

* Net loss for Q3 misses analyst estimates

Outlook

* Company expects full-year 2025 revenue between $54.0 mln and $56.0 mln

* Company sees potential impact from U.S. Government shutdown on award timing

Result Drivers

* FTIR DEMAND - Significant quarter-over-quarter increase in XplorIR placements and initial shipments of new VipIR device

* REVENUE CHANNEL DIVERSITY - 47% of revenues from U.S. state and local channels, reducing reliance on federal contracts

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $14 mln $13.60

Revenue mln (4

Analysts

)

Q3 Net Miss -$15 mln -$4.29

Income mln (3

Analysts

)

Q3 Gross $7.40

Profit mln

Q3 $23.70

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for 908 Devices Inc ( MASS ) is $10.00, about 26.2% above its November 7 closing price of $7.38

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)